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a b s t r a c t
Human serum butyrylcholinesterase (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents. A dose of 200 mg of HuBChE is envisioned
as a prophylactic treatment that can protect humans from an exposure of up to 2  LD50 of soman.
The limited availability and administration of multiple doses of this stoichiometric bioscavenger make
this pretreatment difﬁcult. Thus, the goal of this study was to produce a smaller enzymatically active
HuBChE polypeptide (HBP) that could bind to nerve agents with high afﬁnity thereby reducing the dose
of enzyme. Studies have indicated that the three-dimensional structure and the domains of HuBChE (acyl
pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the
binding of substrate are also essential for the selectivity and binding of inhibitors including OPs. Therefore, we designed three HBPs by deleting some N- and C-terminal residues of HuBChE by maintaining the
folds of the active site core that includes the three active site residues (S198, E325, and H438). HBP-4 that
lacks 45 residues from C-terminus but known to have BChE activity was used as a control. The cDNAs for
the HBPs containing signal sequences were synthesized, cloned into different mammalian expression
vectors, and recombinant polypeptides were transiently expressed in different cell lines. No BChE activity
was detected in the culture media of cells transfected with any of the newly designed HBPs, and the
inactive polypeptides remained inside the cells. Only enzymatically active HBP-4 was secreted into the
culture medium. These results suggest that residues at the N- and C-termini are required for the folding
and/or maintenance of HBP into an active stable, conformation.
Published by Elsevier Ireland Ltd.

1. Introduction
Plasma-derived cholinesterases (ChEs) are effective bioscavengers of highly toxic organophosphorus compounds (OP) including
pesticides and nerve agents [1]. Exogenously administered
plasma-derived human butyrylcholinesterase (HuBChE) protects
animals from multiple LD50s of OP nerve agents without any toxic
effects or performance decrements [2–4]. Thus, HuBChE is
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embryonic kidney cells; HuBChE, human butyrylcholinesterase; OP, organophosphorus compounds.
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currently in advanced development as a prophylactic treatment
for nerve agent toxicity. A dose of 200 mg of HuBChE is estimated
to protect humans from an exposure of up to 2  LD50 of soman [5].
However, the production of native HuBChE in such quantities is
expensive and requires large amounts of plasma. This limited
availability and administration of multiple doses of large quantities
of this stoichiometric bioscavenger make this pretreatment
difﬁcult.
One approach for reducing the dose of this enzyme is to design a
small molecule polypeptide bioscavenger that can be produced in
large quantities using molecular biology techniques. HuBChE is a
globular protein made up of four identical polypeptides of 574
amino acids each. Previous studies have shown that deletion of
45 C-terminal amino acids resulted in secretion of active HuBChE
monomers [6]. Therefore, in this study, the production of smaller
HuBChE polypeptides (HBPs) was attempted by deleting more amino acid residues from both N- and C-termini. The active site S198
in HuBChE is also the site for the binding of OPs. This was clearly
demonstrated by isolating a HuBChE nonapeptide (FGESAGAAS)
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that includes the active site Ser modiﬁed by various OP and non-OP
inhibitors [7]. Results of site-directed mutagenesis, molecular
modeling, and X-ray crystallography studies suggest that the
architecture of the active-site gorge is important for the binding
of OPs to ChEs. The structural features of HuBChE that maintain
the folds of the active site are contained in the polypeptide region
between residues 61 and 478 of HuBChE [8–12]. Accordingly, three
HBPs that lack amino acid residues from either N- or C-terminus
(HBP-1(1478), HBP-2(61529), HBP-3(156529)) were designed.
HBP-4(1529) that lacks 45 residues from C-terminus but known
to have BChE activity was used as a control. The cDNAs for the
HBPs containing signal sequences were synthesized and cloned
into different mammalian expression vectors, which were used
for transfecting different cell lines. BChE activity secreted into
the culture medium and in cell lysates was tested.

2. Materials and methods
2.1. Reagents and cells
Gene juice, nano juice and pTriEx-4Neo plasmid were purchased from EMD Millipore Chemicals (San Diego, CA).
pcDNA™3.1/V5-His TOPO TA expression kit, Lipofectamine 2000,
Lipofectamine Plus, Lipofectamine LTX Plus and 293fectin transfection reagents were obtained from Life Technologies, Inc. (Gaithersburg, MD). Plasmid containing HuBChE (pGS-HuBChE) gene was
generous gift from Dr. Oksana Lockridge (University of Nebraska,
Omaha, NE). Rabbit polyclonal antibodies to puriﬁed plasmaderived HuBChE were produced by Spring Valley Laboratories,
Inc., Woodline, MD.
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2.2. Designing of HBPs
Molecular dynamics simulations and X-ray crystal structure
analysis of HuBChE show that the structural features of HuBChE
that are required for effective binding of OPs are largely contained
in the 61–478 polypeptide region. The essential amino acid residues involved in OP-binding are contained in ﬁve peptide fragments (61–88, 108–148, 187–236, 285–336, and 384–478) [11–
12]. These peptides were identiﬁed by deleting residues surrounding the active site while still maintaining its architecture. The
resulting molecule contained essential binding subsites: (1)
three-pronged oxyanion hole, (2) pi-cation site, (3) acyl-binding
pocket, (4) gorge rim residues, (5) E197 that makes hydrogen
bonds directly or through water molecules with residues at the
catalytic site, and (6) D70, that plays an important role in promoting substrate binding and in controlling the dynamics and structural organization of water molecules. Based on this information,
(1) HBP-1 was designed by deleting 96 amino acid residues from
C-terminus (479–574), (2) HBP-2 was designed by deleting 60 amino acid residues from N-terminus (1–60) and 45 amino acid residues from C-terminus (530–574), (3) HBP-3 was designed by
deleting 155 residues from N-terminus (1–155) and 45 amino acid
residues from C-terminus (530–574) of the HuBChE protein (Figs. 1
and 2). HBP-4 that lacks 45 residues from C-terminus (530–574)
was used as a control.
2.3. Cloning and expression of recombinant HBPs
Genes encoding HBPs containing the signal peptide and Kozak
sequence at their N-terminus were synthesized (Retrogen, Inc.,
San Diego, CA). A signal peptide that drives the secretion of

Fig. 1. Ribbon diagrams or predicted structures of HBPs. Sequences were selected based on the X-ray crystal structure of HuBChE (PDB ID: 1P0I), and N- and C-terminus
regions forming small self-folded domains and predicted to be not required for HuBChE activity were deleted (shown in purple). (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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anti-HuBChE antibody. Proteins were detected by incubation with
a 1:100,000-diluted horseradish peroxidase-conjugated secondary
anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO) and using an
ECL Plus chemiluminescence detection kit (GE Healthcare Life Sciences, Piscataway, NJ).
Fig. 2. Relative sizes of designed HBPs after deleting N- and C-terminal sequences
of HuBChE.

3. Results and discussion
full-length HuBChE into the culture medium [13] was used in this
study. Suitable restriction enzyme sites were placed at the 50 - and
30 -ends of these genes so that they could be cloned into any mammalian expression vector. To generate pTriEx-4Neo- and
pcDNA3.1-HBP expression vectors, HBP inserts were created by
digestion of pCR-Blunt-HBP plasmids with BamHI and NotI, and
the gel-puriﬁed inserts were ligated with BamHI and NotI-digested
vectors (Fig. 3). To generate pGS-HBP expression vectors, the HBP
genes prepared by gel-extraction following digestion of pCRBlunt-HBP plasmids with HindIII and ApaI, were subcloned into
HindIII and ApaI-digested pGS vector. The sequences of HBPs in
all the expression vectors were veriﬁed by DNA sequencing.
The expression of HBPs by the constructs in different vectors
was investigated in various cell lines using transient transfection.
Plasmid DNAs were introduced into HEK-293A, BHK or CHO cells
using different transfection reagents according to the manufacturer’s protocols, and the culture medium was assayed for BChE
activity at 24, 48 and 72 h. Cell lysates were prepared by removing
culture medium from cells at 72 h after transfection and adding
0.2 ml of Cytobuster protein extraction reagent (Novagen, Madison, WI) to the wells. Following incubation at 22 °C for 5 min, lysates were centrifuged at 16,000g for 15 min, and clear
supernatants were assayed for BChE activity.
2.4. Determination of enzyme activity of HBPs
Enzyme activity of HBPs was measured by the Ellman assay [14]
in 50 mM sodium phosphate buffer, pH 8.0, at 22 °C, in the presence of 1 mM 5,50 -dithiobis-(2-nitrobenzoic acid) (DTNB), using
1 mM butyrylthiocholine iodide (BTC) as the substrate.
2.5. Western blot analysis of HBPs
Proteins in culture media or cell lysate separated on a 12% polyacrylamide gel under denaturing and reducing conditions [15]
were transferred to a PVDF membrane [16]. After incubation with
4% nonfat dry milk powder in 50 mM Tris buffer, pH 7.6, 150 mM
NaCl, 0.05% Tween 20, membranes were incubated with polyclonal

HuBChE is a stoichiometric bioscavenger that can bind to and
neutralize all OP nerve agents. However, a large dose of HuBChE
is needed to counteract the toxic effects of OPs. Therefore, in order
to reduce the dose, smaller OP-binding polypeptides were designed by deleting N- and C-terminus regions of HuBChE (Figs. 1
and 2). These deleted sequences form small self-folded ﬂexible domains and were predicted to be not required for HuBChE activity.
HBPs of different lengths and sequences were synthesized and
cloned into various mammalian expression vectors (pcDNA3.1,
pTriEx-4Neo, and pGS) in order to select the best vector for the
expression of HBPs. HBP inserts in pcDNA3.1 plasmid following
digestion with BamHI and NotI are shown in Fig. 3. All the HBP inserts were of correct size and in right orientation. Similarly, the
sizes, orientation and sequences of HBP inserts in other expression
vectors were veriﬁed (data not shown). Preliminary studies
showed that pcDNA3.1 and pGS plasmids, compared to pTriEx4Neo, were better expression vectors for expressing HBP-4 or HuBChE (data not shown).
The next step was to determine the best transfection reagent,
optimum ratio of DNA to transfection reagent and the best cell line
for the expression of HBPs. This was achieved by using varying
amounts of transfection reagents for transfecting different cell
lines with 2 lg of pcDNA3.1-HBP-4 and assaying supernatants for
BChE activity. As shown in Fig. 4, levels of BChE activity expressed
by CHO-K1 cells (ATCC# CCL-61), was in the following order: Lipofectamine LTX Plus > Lipofectamine 2000 > 293fectin > Gene
juice > Lipofectamine Plus > Nano juice. Results of similar evaluations conducted in other cell lines are summarized as follows.
For CHO-K1 cells (ATCC# CRL-9618): Lipofectamine LTX
Plus > Lipofectamine 2000 > Gene juice > 293fectin > Lipofectamine Plus > Nano juice. For BHK50 cells (ATCC# CRL-10314):
Lipofectamine 2000 > 293fectin > Lipofectamine Plus = Lipofectamine LTX Plus > Gene juice > Nano juice. For BHK-21 cells (ATCC#
CCL-10):
Lipofectamine
2000 > 293fectin > Lipofectamine
Plus = Lipofectamine LTX Plus > Gene juice > Nano juice. For HEK293A cells: Lipofectamine 2000 > 293fectin > Lipofectamine LTX
Plus > Lipofectamine Plus > Gene juice > Nano juice. Based on these
results, Lipofectamine 2000 with a ratio of 1:2 (DNA:Lipofectamine

Fig. 3. HBPs in pcDNA3.1 plasmid. pcDNA3.1-HBP plasmids were treated with BamHI and NotI, electrophoresed on 1% agarose gel and stained with ethidium bromide.
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Fig. 4. Expression of HBP-4 in CHO-K1 cells. CHO-K1 cells (ATCC# CCL-61), grown overnight in 12-well plates were transfected with 2 lg of pcDNA3.1-HBP-4 plasmid DNA
using various transfection reagents, according to the manufacturer’s protocols. BChE activity in the culture medium was measured by the Ellman assay [14], using 1 mM BTC
as substrate. Numbers on X-axis indicate the ratios of DNA (lg) to transfection reagent components (ll).

2000) and either HEK-293A or CHO-K1 (ATCC# CCL-61) cells were
selected for the expression of HBPs.
HEK-293A cells transfected with pcDNA3.1 vectors containing
HBPs 1, 2, 3 did not secrete any BChE activity into the culture medium (Fig. 5). Similarly, HEK-293A cells transfected with pTriEx-

4Neo-HBPs and CHO-K1 cells transfected with pcDNA3.1- and
pGS-HBPs did not secrete any BChE activity into the culture medium (data not shown). On the other hand, BChE activity was secreted by all cell lines transfected with expression vectors
containing HBP-4 (Figs. 4 and 5). These results indicate that the
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Fig. 5. Expression of HBPs in HEK-293A cells. Cells grown overnight in 12-well
plates were transfected with 2 lg of pcDNA3.1-HBP plasmid DNAs and 4 ll of
Lipofectamine 2000. BChE activity in the culture medium was measured by the
Ellman assay [14]. FL-BChE represents full length HuBChE positive control and Neg,
Lipofectamine 2000 negative control.

deletion of 45 amino acid residues from HuBChE C-terminus that
form the tetramerization domain does not adversely affect the
expression, secretion and enzymatic activity of HuBChE, which is
consistent with previous observations [6]. On the contrary, as previously noted [6], this deletion resulted in increased expression
and secretion of monomers into the culture medium (HBP-4,
Fig. 5). However, the deletion of additional 51 amino acids from
HBP-4 or 96 amino acids from the HuBChE C-terminus (HBP-1)
completely abolished the secretion of active HuBChE into the culture medium. Similarly, the deletion of even 60 amino acid residues from the N-terminus (HBP-2) had a severe effect on the
secretion of active HuBChE into the culture medium.
To determine if deletions of amino acid residues at the N- and
C-termini affected activity of expressed polypeptides or their
secretion into culture media, cell lysates of HEK-293A cells transfected with pcDNA3.1-HBPs-1, 2, 3 expression vectors were also
assayed for BChE activity. No BChE activity was detected in cell
lysates. Furthermore, both culture media and cell lysates of HEK293A cells transfected with pcDNA3.1-HBPs-1, 2, 3 expression
vectors were subjected to Western blotting. As shown in Fig. 6,
BChE polypeptides were detected in cell lysates, suggesting that
inactive polypeptides were retained in cells. No HBPs were detected in the culture media (data not shown). Thus, truncation of
residues at N- and C-termini affect the activity as well as secretion
of expressed HBPs.
Our observations corroborate the ﬁndings of previous studies,
which attempted to produce truncated HuBChEs and acetylcholinesterases (AChEs). Blong et al. [6] showed that deletion of 51
or more amino acids from the C-terminus of HuBChE destroyed
BChE activity and caused the inactive protein to remain in the cell.
Deletion of 8 or more amino acids from the N-terminus also resulted in inactive protein that remained inside the cell [6]. Similarly, a truncated AChE that lacks the C-terminal 40 amino acids
was secreted into the medium, whereas the mutant AChE that
lacks 65 amino acids from C-terminus was inactive, suggesting that
these domains contribute to proper folding and catalytic activity
[17]. By measuring both catalytic activity and isotopic labeling,
pulse-chase studies showed that only the catalytically active molecules are further processed by the cell, whereas the inactive molecules are rapidly degraded intracellularly [18]. In conclusion,
studies conducted with HuBChE suggest that the inactivity of the
designed HBPs is likely due to incorrect folding, and the amino acid
residues at both the N- and C-termini are required for the folding
and/or maintenance of HBP into an active, stable conformation.

Fig. 6. Western blot analysis of HBPs in cell lysates. HEK-293A cells were
transfected with pcDNA3.1-HBP plasmid DNAs. After 72 h of transfection, culture
medium was removed and cells were lysed with SDS PAGE reducing sample buffer.
Following SDS PAGE on a 12% gel, proteins were transferred to a PVDF membrane,
and HBPs were detected using polyclonal rabbit anti-HuBChE antibodies. M,
Millipore perfect protein Western markers, N, native plasma-derived HuBChE; L,
lipofectamine negative control, C, full-length HuBChE positive control; 1–4 represent HBPs 1–4.
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